Press Releases

Shanghai, China, March 12, 2026——WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced that it has been honored with the “Best ADC CDMO in Asia” and “Best ADC CRDMO in Asia” at the 2026 Asia-Pacific Biopharma Excellence Awards. This marks the second consecutive year of receiving such prestigious recognition. Notably, the “Best ADC CRDMO in Asia” award was specially conferred by IMAPAC for the first time this year. This recognition not only affirms WuXi XDC’s one-stop comprehensive service capabilities in the ADC field but also acknowledges its ongoing innovation and industry leadership.

As a global leader in ADC/XDC CDMO services, WuXi XDC specializes in providing end-to-end solutions for bioconjugates such as ADCs, spanning discovery (R), development (D), and manufacturing (M). By integrating the entire R&D and production value chain, the company effectively addresses key challenges associated with traditional multi-entity collaboration models, including fragmented workflows and prolonged timelines, while ensuring seamless technology transfer and high-quality compliance.

With its cutting-edge conjugation technologies, proprietary payload-linker platforms, and extensive expertise in bioconjugates development, WuXi XDC has developed the WuXiDARx™ platform, X-LinC linker technology, and WuXiTecan-1 and WuXiTecan-2 payload-linker technologies. These innovations provide clients with efficient and flexible technical solutions, facilitating the rapid advancement of ADCs and other bioconjugates into clinical stages and highlighting the company’s outstanding early-stage discovery and development service capabilities. Notably, the company recently entered into a strategic collaboration with Earendil Labs on the WuXiTecan-2 payload-linker technology platform, with a potential total value of $885 million.

Leveraging its global manufacturing sites, WuXi XDC possesses large-scale commercial manufacturing capacity. Backed by deep technical expertise, high-standard quality management systems, and strong execution capability, the company has consistently achieved high-quality delivery of orders for global clients and earned their trust.

Dr. Jimmy Li, CEO of WuXi XDC, stated, “We are truly honored to receive the ‘Best ADC CDMO in Asia’ and ‘Best ADC CRDMO in Asia’ awards. This recognition not only reflects our team’s commitment to excellence but also reaffirms our dedication to providing world-class integrated services to our clients. In response to the growing demand for diversified bioconjugates development and technology exploration, we will continue to leverage our end-to-end CRDMO platform to optimize ADCs and XDCs development processes, empower our clients in accelerating the commercializaiton of bioconjugates, and bring more treatment options and hope to patients worldwide.”

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts 

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com